Login
$MNPR
$71.97 -$0.03 (0.04%) Live

$MNPR 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced t...

12 Aug 2026 8-K: Results of Operations and Financial Condition

Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced sec...

22 Jul 2026 8-K: Regulation FD Disclosure

WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, t...

30 Jun 2026 8-K: Regulation FD Disclosure

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, t...

26 Jun 2026 8-K: Regulation FD Disclosure

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

23 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 22, 2026, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,698,778 shares of the Company’s common stock were entitled to vote as of April 27, 2026, the record date for the Annual Meetin...

29 May 2026 8-K: Regulation FD Disclosure

On May 29, 2026, Monopar Therapeutics Inc. (“Monopar”) presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology and clinical symptoms in patients with Wilson disease...

19 May 2026 8-K: Regulation FD Disclosure

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

14 May 2026 8-K: Results of Operations and Financial Condition

Wilmette, IL, May 14, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first ...

20 Apr 2026 8-K: Regulation FD Disclosure

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

27 Mar 2026 8-K: Results of Operations and Financial Condition

Wilmette, Ill., March 27, 2026 – Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announce...

02 Mar 2026 8-K: Regulation FD Disclosure

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

13 Nov 2025 8-K: Results of Operations and Financial Condition

Wilmette, IL, November 13, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced t...

10 Nov 2025 8-K: Regulation FD Disclosure

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

24 Sep 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Pre-Funded Warrants to Purchase up to 960,542 Shares of Common Stock

15 Sep 2025 8-K: Regulation FD Disclosure

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

12 Aug 2025 8-K: Results of Operations and Financial Condition

Wilmette, IL, August 12, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today an...

23 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2025, Monopar Therapeutics Inc. (“Monopar” or the “Company”) held its Annual Meeting. A total of 6,115,214 shares of the Company’s common stock were entitled to vote as of April 25, 2025, the record date for the Annual Meetin...

13 May 2025 8-K: Results of Operations and Financial Condition

Wilmette, IL, May 13, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today annou...

07 May 2025 8-K: Regulation FD Disclosure

WILMETTE, Ill, May 7, 2025 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long ter...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support